BACKGROUND: The heterogeneity of CD4 T-cell counts and HIV-1 RNA at 5-12 years after the initiation of highly active antiretroviral therapy (HAART) remains largely uncharacterized. METHODS: In the Multicenter AIDS Cohort Study, 614 men who initiated HAART contributed data 5-12 years subsequently. Multivariate regression was used to evaluate the predictors of CD4 counts and HIV-1 RNA levels. RESULTS: At 5 to 12 years post-HAART, the median CD4 T-cell count was 586 (interquartile range, 421-791) cells per microliter and 78% of the HIV-1 RNA measurements were undetectable. Higher CD4 T-cell counts 5-12 years post HAART were predicted by higher CD4 T-cell counts and higher total lymphocyte count pre HAART, lack of hepatitis B or C virus coinfections, and greater CD4 T-cell change and suppressed HIV-1 RNA in the first 5 years after starting HAART. Men who were 50 years and older with 351-500 CD4 cells per microliter at HAART initiation had adjusted mean CD4 T-cell count of 643 cells per microliter at 10-12 years post HAART, which was similar to the adjusted mean CD4 T-cell count (670 cells/μL, P = 0.45) in this period for younger men starting HAART with lower CD4 T-cell counts. HIV-1 RNA suppression in the first 5 years post HAART predicted subsequent viral suppression. CONCLUSIONS: Immunological and virological responses in the first 5 years post HAART predicted subsequent CD4 T-cell counts and HIV-1 RNA levels. The association between age and subsequent CD4 T-cell count supports incorporating age in the guidelines for use of HAART.
BACKGROUND: The heterogeneity of CD4 T-cell counts and HIV-1 RNA at 5-12 years after the initiation of highly active antiretroviral therapy (HAART) remains largely uncharacterized. METHODS: In the Multicenter AIDS Cohort Study, 614 men who initiated HAART contributed data 5-12 years subsequently. Multivariate regression was used to evaluate the predictors of CD4 counts and HIV-1 RNA levels. RESULTS: At 5 to 12 years post-HAART, the median CD4 T-cell count was 586 (interquartile range, 421-791) cells per microliter and 78% of the HIV-1 RNA measurements were undetectable. Higher CD4 T-cell counts 5-12 years post HAART were predicted by higher CD4 T-cell counts and higher total lymphocyte count pre HAART, lack of hepatitis B or C virus coinfections, and greater CD4 T-cell change and suppressed HIV-1 RNA in the first 5 years after starting HAART. Men who were 50 years and older with 351-500 CD4 cells per microliter at HAART initiation had adjusted mean CD4 T-cell count of 643 cells per microliter at 10-12 years post HAART, which was similar to the adjusted mean CD4 T-cell count (670 cells/μL, P = 0.45) in this period for younger men starting HAART with lower CD4 T-cell counts. HIV-1 RNA suppression in the first 5 years post HAART predicted subsequent viral suppression. CONCLUSIONS: Immunological and virological responses in the first 5 years post HAART predicted subsequent CD4 T-cell counts and HIV-1 RNA levels. The association between age and subsequent CD4 T-cell count supports incorporating age in the guidelines for use of HAART.
Authors: P M Tarwater; J B Margolick; J Jin; J P Phair; R Detels; C Rinaldo; J Giorgi; A Muñoz Journal: J Acquir Immune Defic Syndr Date: 2001-06-01 Impact factor: 3.731
Authors: C A Kleeberger; J P Phair; S A Strathdee; R Detels; L Kingsley; L P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2001-01-01 Impact factor: 3.731
Authors: Sophie Grabar; Isabelle Kousignian; Alain Sobel; Philippe Le Bras; Jacques Gasnault; Patricia Enel; Corinne Jung; Aba Mahamat; Jean-Marie Lang; Dominique Costagliola Journal: AIDS Date: 2004-10-21 Impact factor: 4.177
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: B T Røge; T S Barfod; O Kirk; T L Katzenstein; N Obel; H Nielsen; C Pedersen; L R Mathiesen; J D Lundgren; J Gerstoft Journal: HIV Med Date: 2004-09 Impact factor: 3.180
Authors: S T Wright; K Petoumenos; M Boyd; A Carr; S Downing; C C O'Connor; M Grotowski; M G Law Journal: HIV Med Date: 2012-10-04 Impact factor: 3.180
Authors: Hamish McManus; Catherine C O'Connor; Mark Boyd; Jennifer Broom; Darren Russell; Kerrie Watson; Norman Roth; Phillip J Read; Kathy Petoumenos; Matthew G Law Journal: PLoS One Date: 2012-11-07 Impact factor: 3.240
Authors: Pablo F Belaunzarán-Zamudio; Livio Azzoni; David H Canaday; Yanink N Caro-Vega; Brian Clagett; Mohammed S Rassool; Benigno Rodriguez; Ian Sanne; Irini Sereti; Juan G Sierra-Madero; Michael M Lederman Journal: Pathog Immun Date: 2017-05-09